This study aims to evaluate the effect of an AI-assisted "Smart family doctor" digital health management tool on improving the control rates of hypertension, diabetes, and dyslipidemia in post-CABG (coronary artery bypass grafting) patients or post-PCI (percutaneous coronary intervention) patients. A randomized controlled trial design will be used, involving approximately 5-10 hospitals and 536 participants. Eligible participants are adults aged 18 or older, post-CABG or post-PCI patients with hypertension, diabetes, and dyslipidemia.
Age ≥ 18 years.
History of CABG surgery or PCI with history of hypertension, diabetes, and dyslipidemia.
Systolic blood pressure no less than 130 mmHg or diastolic blood pressure no less than 80 mmHg
HbA1c no less than 7%
History of heart failure or severe arrhythmias.
Presence of other severe underlying conditions such as cancer or liver and kidney insufficiency.
Pregnancy, lactation, or plans for pregnancy within the next year.
Cognitive, communication impairments, or limitations in daily activities.
China National Center for Cardiovascular Diseases
Lead sponsor
Chinese Academy of Medical Sciences, Fuwai Hospital
Collaborator